|
Outcome
|
Variable
|
Hazard ratio
|
95% CI
|
P
|
|---|
|
Intracranial PFS
|
SRS and nivolumab
|
0.54
|
0.32–0.92
|
0.038
|
|
fmulti-fraction SRS
|
0.48
|
0.28–0.87
|
0.015
|
|
OS
|
SRS and nivolumab
|
0.51
|
0.28–0.81
|
0.019
|
|
multi-fraction SRS
|
0.54
|
0.33–0.96
|
0.043
|
|
KPS >70
|
0.34
|
0.23–0.78
|
0.010
|
|
absent extracranial disease
|
0.50
|
0.29–0.81
|
0.018
|
- Abbreviations: OS, overall survival; PFS, progression-free survival;HR, hazard ratio; CI, confidence interval; *Variables with a significance of p < 0.05 at univariate analysis were included in the multivariate analysis. The following variables were evaluated: age, gender, Karnofsly Perforance Status (KPS) score, histology, extracranial disease status, systemic therapy, number of metastases, time to brain metasases development, conformity index, and irradiated volumes
